The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Addressing race and sex-based disparities in lung cancer screening eligibility
Matthew Smeltzer, PhD, The University of Memphis, Memphis, TN, discusses the impact of modified lung cancer screening (LCS) criteria on eligibility and disparities. The shift to 20 years reduced race and sex-based disparities while reaching socially disadvantaged groups, maintaining diagnostic efficiency. This suggests broader criteria improve access to LCS without compromising effectiveness. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Other Relationship – Association of Community Cancer Centers (ACCC)
